
AMR: ENABLE selects Mutabilis candidate
Efficacy of beta-lactam antibiotics, which represent 65% of the antibiotics sold throughout the world, is increasingly challenged in Gram-negative...

BioVersys receives up to €8m from CARB-X
Privately-owned BioVersys AG, headquartered in Basel, is focusing on research and development of small molecules for multidrug-resistant bacterial...

Researchers unravel how ADEP antibiotics work
Fighting antimicrobial resistance has been named one of the prioritary goals by the World Health Organization (WHO). However, as the number of...

Abcam buys Expedeon’s immunology business
“This purchase price is equivalent to twice Expedeon’s current market capitalisation or excess of 9-times 2018 annual group revenue,” the company...

Polyphor presents AMR breaker
In Nature, Anatol Luther et al. from Polyphor AG and the University of Zurich describe the discovery and characterisation of a new class of...

European circular bioeconomy fund near closing
Hauck & Aufhäuser Fund Services S.A. will act as the Alternative Investment Fund Manager. The ECFB will provide access to equity, debt or...

Spanish sector attracting more and more investment
According to Spain's biotech association, the investor day attracted 60 investors from nine countries and provided more than 500 partnering...